Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluticasone furoate
Drug ID BADD_D00946
Description Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Indications and Usage Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.
Marketing Status Prescription; OTC
ATC Code D07AC17; R01AD08; R01AD12; R03BA05; R03BA09
DrugBank ID DB08906
KEGG ID D06315
MeSH ID C523187
PubChem ID 9854489
TTD Drug ID D0Y7JU
NDC Product Code 63379-083; 59057-009; 52482-008; 47848-057; 0173-0876; 64918-1915; 55018-302; 0135-0616; 64918-1916; 0135-0615; 15308-2021; 58175-0553; 0173-0874; 59057-010; 63379-084; 49076-6451; 64918-1117; 22552-0042; 0173-0888; 63592-3370; 49076-6452; 64918-1910
Synonyms fluticasone furoate
Chemical Information
Molecular Formula C27H29F3O6S
CAS Registry Number 397864-44-7
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal insufficiency05.01.02.001; 14.11.01.0040.004171%
Adrenocortical insufficiency acute14.11.01.020; 05.01.02.0050.002780%Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anosmia17.04.04.001; 22.04.03.0060.002780%
Asthma22.03.01.002; 10.01.03.0100.004171%Not Available
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Blood cortisol decreased13.10.09.0040.004171%Not Available
Blood glucose increased13.02.02.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cataract06.06.01.0010.002780%
Cataract subcapsular06.06.01.002--Not Available
Chronic obstructive pulmonary disease22.03.01.0070.002780%Not Available
Confusional state19.13.01.001; 17.02.03.0050.004171%
Conjunctivitis11.01.06.012; 06.04.01.002--
Cough22.02.03.001--
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.0010.004171%Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption10.01.01.005; 08.01.06.015; 23.03.05.0010.002780%Not Available
Dry throat22.02.05.004; 07.06.01.005--Not Available
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.0020.006951%
Epistaxis24.07.01.005; 22.04.03.001--
The 1th Page    1 2 3    Next   Last    Total 3 Pages